EMILY MOORE: Open Payments
NPI 1114607553 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,114 in 94 payments from 18 companies in 2025. Trend: 2023 $78 · 2024 $1,430 · 2025 $2,114
Food & beverage: $2,030Education: $84
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $546 |
| ABBVIE INC. | 29 | $524 |
| Madrigal Pharmaceuticals | 8 | $224 |
| Janssen Biotech, Inc. | 8 | $196 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $106 |
| Ipsen Biopharmaceuticals, Inc | 4 | $74 |
| CVRx, Inc. | 3 | $55 |
| Ardelyx, Inc. | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Lilly USA, LLC | 2 | $45 |
Products named: ENTYVIO, REZDIFFRA, RINVOQ, GATTEX, TREMFYA, LINZESS, CREON, XIFAXAN.
Industry payments across TX — which companies pay providers there.
